Home/Filings/4/0001628280-21-015647
4//SEC Filing

Murphy Matthew B. 4

Accession 0001628280-21-015647

CIK 0001808805other

Filed

Aug 3, 8:00 PM ET

Accepted

Aug 4, 8:01 PM ET

Size

5.7 KB

Accession

0001628280-21-015647

Insider Transaction Report

Form 4
Period: 2021-06-14
Murphy Matthew B.
General Counsel
Transactions
  • Award

    Stock Option (Right to Buy)

    2021-06-14+326,526326,526 total
    Exercise: $10.10Exp: 2031-06-14Common Stock (326,526 underlying)
Footnotes (1)
  • [F1]Subject to the reporting person continuing to be a Service Provider (as defined in the Company's 2021 Equity Incentive Plan), 25% of the shares subject to such Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date (as defined below), and the balance of the shares subject to such Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary. The Vesting Commencement Date is April 1, 2021.

Issuer

Nautilus Biotechnology, Inc.

CIK 0001808805

Entity typeother

Related Parties

1
  • filerCIK 0001865778

Filing Metadata

Form type
4
Filed
Aug 3, 8:00 PM ET
Accepted
Aug 4, 8:01 PM ET
Size
5.7 KB